Browse > Article
http://dx.doi.org/10.15324/kjcls.2018.50.1.20

Performance Evaluation of In Vitro Diagnostic Reagents for Mycobacterium tuberculosis and Non-tuberculous Mycobacteria by FDA Approval  

Kim, Yeun (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Park, Sunyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Kim, Jungho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Chang, Yunhee (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Ha, Sunmok (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Choi, Yeonim (Department of Biomedical Laboratory Science, Songho College)
Lee, Hyeyoung (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.50, no.1, 2018 , pp. 20-28 More about this Journal
Abstract
Tuberculosis (TB) is a bacterial infection disease caused by members of the species Mycobacterium tuberculosis (MTB) complex. Approximately one third of the world's population is infected with TB. In Korea, approximately 40,000 new patients are identified each year. Moreover, infections from non-tuberculous mycobacteria (NTM) have also increased. In the diagnosis of TB and NTM, traditional bacterial cultures are required for 3 to 4 weeks. Therefore, rapid and accurate diagnostic tests for TB and NTM are needed. To distinguish between TB and NTM, a range of diagnostic methods have been developed worldwide. In vitro diagnostic assays are constantly being developed to meet the increasing need for the rapid and accurate identification for TB and NTM. On the other hand, the performance evaluations of in vitro diagnostic reagents for TB and NTM are lacking. Recently, the Korea Food and Drug Administration (KFDA) issued a guideline for in vitro diagnostic reagents for MTB and NTM. Here, this study analyzed the performance of currently developed in vitro diagnostic reagents for TB and NTM in the US FDA. This analysis of US FDA approved molecular assays could serve as a useful reference for an evaluation of the reagent performance of TB and NTM.
Keywords
Tuberculosis; Sensitivity; Specificity; Diagnostic test approval; Food and drug administration;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Lee AS, Jelfs P, Sintchenko V, Gilbert GL. Identification of non-tuberculous mycobacteria: utility of the GenoType Mycobacterium CM/AS assay compared with HPLC and 16S rRNA gene sequencing. J Med Microbiol. 2009;58(7):900-904.   DOI
2 Singh AK, Maurya AK, Umrao J, Kant S, Kushwaha RA, Nag VL, et al. Role of $GenoType^{(R)}$ common Mycobacteria/Additional Species Assay for Rapid Differentiation Between Mycobacterium tuberculosis Complex and Different Species of Non-Tuberculous Mycobacteria. J Lab Physicians. 2013;5(2):83-89.   DOI
3 Garcia-Agudo L, Jesus I, Rodriguez-Iglesias M, Garcia-Martos P. Evaluation of INNO-LiPA mycobacteria v2 assay for identification of rapidly growing mycobacteria. Braz J Microbiol. 2011;42(3):1220-1226.   DOI
4 Padilla E, Gonzalez V, Manterola JM, Perez A, Quesada MD, Gordillo S, et al. Comparative evaluation of the new version of the INNO-LiPA Mycobacteria and genotype Mycobacterium assays for identification of Mycobacterium species from MB/BacT liquid cultures artificially inoculated with Mycobacterial strains. J Clin Microbiol. 2004;42(7):3083-8088.   DOI
5 Trueba F, Fabre M, Saint-Blancard P. Rapid identification of Mycobacterium genavense with a new commercially available molecular test, INNO-LiPA Mycobacteria v2. J Clin Microbiol. 2004;42(9):4403-4404.   DOI
6 Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA. 2002;99(6):3684-3689.   DOI
7 Food and Drug Administration. 510(k). K131706. Report. Washington: Department of Health and Human Service; 2013 December.
8 Huang H, Zhang Y, Li S, Wang J, Chen J, Pan Z, et. al. Rifampicin resistance and multidrug-resistant Tuberculosis detection using Xpert MTB/RIF in Wuhan, China: a retrospective study. Microb Drug Resist. 2017 Oct 20. doi:10.1089/mdr.2017.0114. [Epub ahead of print].
9 Sanne CVK, Aigul T, Aliya K, Zauresh M, Lyazzat B, Moldir A, et al. Effect of introducing Xpert MTB/RIF to test and treat Individuals at risk of multidrug- resistant Tuberculosis in Kazakhstan: A prospective cohort study. PLos one. 2015;10(8):e0136368.   DOI
10 Geleta DA, Megerssa YC, Gudeta AN, Akalu GT, Debele MT, Tulu KD. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. BMC Microbiol. 2015;15:220.   DOI
11 Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(6):451-461.   DOI
12 Antonenka U, Hofmann-Thiel S, Turaev L, Esenalieva A, Abdulloeva M, Sahalchyk E, et al. Comparison of Xpert MTB/RIF with ProbeTec ET DTB and COBAS TaqMan MTB for direct detection of M. tuberculosis complex in respiratory specimens. BMC Infect Dis. 2013;20(13):280.
13 Chen X, Yang Q, Kong H, Chen Y. Real-time PCR and amplified $MTD^{(R)}$ for rapid detection of Mycobacterium tuberculosis in pulmonary specimens. Int J Tuberc Lung Dis. 2012;16(2):235-239.   DOI
14 Kimber Richter. Premarket approval of Roche molecular systems $AMPLICOR^{(R)}$ Mycobacterium Tuberculosis test. Food and Drug Administration; 1996 September.
15 Ueyama M, Chikamatsu K, Aono A, Murase Y, Kuse N, Morimoto K, et al. Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan. Tuberculosis (Edinb). 2014;94(1):15-19.   DOI
16 Fegou E, Jelastopulu E, Sevdali M, Anastassiou ED, Dimitracopoulos G, Spiliopoulou I. Sensitivity of the Cobas Amplicor system for detection of Mycobacterium tuberculosis in respiratory and extrapulmonary specimens. Clin Microbiol Infect. 2005;11(7):593-596.   DOI
17 Papaventsis D, Ioannidis P, Karabela S, Nikolaou S, Syridou G, Marinou I, et al. Impact of the Gen-Probe Amplified $MTD^{(R)}$ Test on tuberculosis diagnosis in children. Int J Tuberc Lung Dis. 2012;16(3):384-390.   DOI
18 Guerra RL, Hooper NM, Baker JF, Alborz R, Armstrong DT, Maltas G, et al. Use of the amplified Mycobacterium tuberculosis direct test in a public health laboratory: test performance and impact on clinical care. Chest. 2007;132(3):946-951.   DOI
19 David WD, Amelia M, Nicole P, Christopher B, Susan ED. Cost-effectiveness analysis of the Gen-Probe amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Microbiol 2003;41(3):948-953.   DOI
20 Mitarai S, Kurashima A, Tamura A, Nagai H, Shishido H. Clinical evaluation of Amplicor Mycobacterium detection system for the diagnosis of pulmonary mycobacterial infection using sputum. Tuberculosis. 2001;81(5):319-325.   DOI
21 Choi WS, Choo SK. Effectiveness of clinical examination for detection of respiratory tuberculosis. Korean J Clin Lab Sci. 2006;38(1):54-58.
22 Cho WH, Won EJ, Choi HJ, Kee SJ, Shin JH, Ryang DW, et al. Comparison of AdvanSure TB/NTM PCR and COBAS TaqMan MTB PCR for detection of Mycobacterium tuberculosis complex in routine clinical practice. Ann Lab Med. 2015;35(3):356-361.   DOI
23 Huh HJ, Kwon HJ, Ki CS, Lee NY. Comparison of the genedia MTB detection kit and the cobas TaqMan MTB assay for detection of Mycobacterium tuberculosis in respiratory specimens. J Clin Microbiol. 2015;53(3):1012-1014.   DOI
24 Tran AC, Halse TA, Escuyer VE, Musser KA. Detection of Mycobacterium avium complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings. Diagn Microbiol Infect Dis. 2014;79(1):43-78.   DOI
25 Lee MR, Chung KP, Wang HC, Lin CB, Yu CJ, Lee JJ, et al. Evaluation of the Cobas TaqMan MTB real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory specimens. J Med Microbiol. 2013;62(8):1160-1164.   DOI
26 Moon JW, Chang YS, Kim SK, Kim YS, Lee HM, Kim SK, et al. The clinical utility of polymerase chain reaction for the diagnosis of pleural tuberculosis. Clin Infect Dis. 2005;41(5):660-666.   DOI
27 Lim TK, Mukhopadhyay A, Gough A, Khoo KL, Khoo SM, Lee KH, et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. Chest. 2003;124(3):902-908.   DOI
28 Louro AP, Waites KB, Georgescu E, Benjamin WH Jr. Direct identification of Mycobacterium avium complex and Mycobacterium gordonae from MB/BacT bottles using AccuProbe. J Clin Microbiol. 2001;39(2):570-573.   DOI
29 Lebrun L, Espinasse F, Poveda JD, Vincent-Levy-Frebault V. Evaluation of nonradioactive DNA probes for identification of mycobacteria. J Clin Microbiol. 1992;30(9):2476-2478.   DOI
30 Makinen J, Marjamaki M, Marttila H, Soini H. Evaluation of a novel strip test, GenoType Mycobacterium CM/AS, for species identification of mycobacterial cultures. Clin Microbiol Infect. 2006;12(5):481-483.   DOI
31 Richter E, Rusch-Gerdes S, Hillemann D. Evaluation of the GenoType Mycobacterium assay for identification of mycobacterial species from cultures. J Clin Microbiol. 2006;44(5):1769-1775.   DOI
32 Joint committee for the revision of Korean guidelines for Tuberculosis Korea centers for disease control and Prevention. Korean guidelines for Tuberculosis 2nd edition. 2014. p1-270.
33 WHO. Global tuberculosis report 2017. Report. Geneva: WHO institute; 2017 October.
34 Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB. Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. Eur Respir J. 2017;49(4) pii: 1700374. doi: 10.1183/1399300 3.00374-2017.
35 Food and Drug Administration. Microbiology device, reclassification of nucleic acid-based systems for Mycobacterium tuberculosis complex. Report. Washington: Department of Health and Human Service; 2013 Jan.
36 Food and Drug Administration. Microbiology device. Class II special controls guideline: nucleic acid-based in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex in respiratory specimens. Report. Washington: Department of Health and Human Service; 2014 May.
37 Food and Drug Administration. Department of Health and Human service. Microbiology Device. Class II special controls guideline: nucleic acid-based in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex and genetic mutations associated with Mycobacterium tuberculosis complex antibiotic resistance in respiratory specimens. Report. Washington: Department of Health and Human Service; 2014 October.
38 Food and Drug Administration. Non-tuberculous Mycobacterial lung infection public meeting. The voice of the patient. Report. Washington: Department of Health and Human Service; 2016 May.
39 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.   DOI
40 Target amplification test for the direct detection of Mycobacterium tuberculosis. Summary of safety and effectiveness data. San Diego. GEN-Probe; 1999 September.